Latest News of BRX
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares
By Yahoo! Finance |
1 day ago
Inhibrx Biosciences has 7 investors with a majority stake of 50%. Institutions hold 43% ownership, facing the biggest gain or loss. Hedge funds and individuals also hold significant stakes, with Vikin...
Brixmor Property Group Inc (BRX) Q3 2024 Earnings Call Highlights: Record Occupancy and ...
By Yahoo! Finance |
2 weeks ago
James Taylor, CEO, highlights positive outlook for external growth and institutional interest in retail market, justifying equity raise. Brian Finnegan, President, mentions strong tenant commitments a...
Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...
By Yahoo! Finance |
1 month ago
The FDA meeting de-risked Annamycin's development for AML treatment, allowing higher dosing in the US. The MIRACLE Phase 3 trial has an adaptive design with a primary endpoint of complete remission....
-
Inhibrx: The Biotech Spinoff Poised For Big Gains
By Forbes | 2 months agoAn experienced investor shares insights on finding hidden gems in overlooked areas of the market, focusing on spinoff companies like Inhibrx Biosciences. With innovative biotech treatments targeting c...
-
Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX)
By Yahoo! Finance | 2 months agoInhibrx Biosciences Inc (NASDAQ:INBX) is a biotech company developing therapeutic candidates for various medical needs. Recent insider transactions show more buying than selling, indicating confidence...
-
ImmunityBio, Inc. (IBRX) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 4 months agoImmunityBio, Inc. announced the treatment of patients in the U.S. with ANKTIVA for BCG-unresponsive bladder cancer. The FDA approved this immunotherapy on April 22, 2024....